search
Back to results

Perioperative Lidocaine and Ketamine in Abdominal Surgery

Primary Purpose

Postoperative Pain

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Lidocaine and ketamine
Lidocaine
Ketamine
Placebo
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain focused on measuring Multimodal analgesia, Lidocaine, Ketamine, Abdominal surgery

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults 18 to 80 years old
  • Elective inpatient open or laparoscopic abdominal surgery
  • General anesthesia lasting 2 hours or longer.

Exclusion Criteria:

  • 1. Planned postoperative mechanical ventilation
  • 2. Planned regional anesthesia/analgesia
  • 3. Perioperative gabapentin, magnesium, or nitrous oxide use
  • 4. Pregnancy or breastfeeding
  • 5. Morbid obesity (BMI ≥ 35 kg/m2)
  • 6. American Society of Anesthesiologists (ASA) physical status IV-V
  • 7. Allergy to study medications
  • 8. Contraindication to lidocaine (severe cardiac arrhythmia)
  • 9. Contraindication to ketamine (psychiatric disorder, substance abuse, uncontrolled hypertension, pulmonary hypertension, increased intracranial or intraocular pressure, use of monoamine oxidase inhibitors)
  • 10. Chronic preoperative opioid use (≥ 90 morphine mg equivalents per day for > 3 months)
  • 11. Significant preoperative hepatic dysfunction (alanine aminotransferase or aspartate aminotransferase levels > 5 times normal) or planned liver transplantation
  • 12. Preoperative cardiac failure (left ventricular ejection fraction ≤ 40%)
  • 13. Unable to communicate or comprehend study instructions

Sites / Locations

  • Cleveland Clinic FloridaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Lidocaine and placebo

Ketamine and placebo

Lidocaine and ketamine

Placebo and placebo

Arm Description

Lidocaine and placebo

Ketamine and placebo

Lidocaine and ketamine

Placebo and placebo

Outcomes

Primary Outcome Measures

Pain scores
Pain scores based on the visual analog scale and Brief Pain Inventory. Ranges from 0 to 10, with 0 being no pain and 10 being the worst imaginable pain. The intervention will be deemed effective if both outcomes are non-inferior, and at least one is superior, to the control group.
Total opioid consumption
Total opioid consumption in oral morphine equivalents (mg) from the time of transfer to PACU through to the second postoperative morning. The intervention will be deemed effective if both outcomes are non-inferior, and at least one is superior, to the control group.

Secondary Outcome Measures

Overall benefit of analgesia score (OBAS)
Measures 7 different items, i.e. current pain, vomiting, itching, sweating, freezing, dizziness, and patient satisfaction related to pain management. Each item is scored from 0 to 4, with the total OBAS score ranging from 0 to 28. The lower the total OBAS score, the higher the benefit of analgesia.
Quality of recovery (QoR-15) score
Measures 15 different items, i.e. ability to breathe easily, enjoy food, feel rested, have a good sleep, look after personal toilet and hygiene unaided, communicate with family or friends, getting support from hospital doctors and nurses, return to work or usual home activities, feel comfortable and in control, have a feeling of general well-being, as well as the presence of moderate pain, severe pain, nausea or vomiting, feeling worried or anxious, and feeling sad or depressed. Each item is scored from 0 to 10, with a total QoR-15 score ranging from 0 to 150. The higher the QoR-15 score, the better the quality of recovery in the postoperative period.

Full Information

First Posted
February 5, 2019
Last Updated
February 13, 2023
Sponsor
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT04084548
Brief Title
Perioperative Lidocaine and Ketamine in Abdominal Surgery
Official Title
Lidocaine and Ketamine in Abdominal Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 15, 2019 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Cleveland Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators propose to test the hypothesis that perioperative infusions of lidocaine and/or ketamine reduce opioid consumption and pain scores in adults recovering from elective inpatient abdominal surgery.
Detailed Description
The investigators propose a prospective, randomized, double-blind, placebo-controlled clinical trial (RCT) with a factorial design. Adults 18 to 80 years old having elective inpatient open or laparoscopic abdominal surgery with general anesthesia lasting 2 hours or longer will be included in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Multimodal analgesia, Lidocaine, Ketamine, Abdominal surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Model Description
Double-blind factorial randomization to lidocaine or placebo and ketamine or placebo.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Pharmacy-prepared medications.
Allocation
Randomized
Enrollment
420 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lidocaine and placebo
Arm Type
Experimental
Arm Description
Lidocaine and placebo
Arm Title
Ketamine and placebo
Arm Type
Experimental
Arm Description
Ketamine and placebo
Arm Title
Lidocaine and ketamine
Arm Type
Experimental
Arm Description
Lidocaine and ketamine
Arm Title
Placebo and placebo
Arm Type
Placebo Comparator
Arm Description
Placebo and placebo
Intervention Type
Drug
Intervention Name(s)
Lidocaine and ketamine
Intervention Description
Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
Intervention Type
Drug
Intervention Name(s)
Lidocaine
Intervention Description
Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Perioperative placebo infusion (normal saline)
Primary Outcome Measure Information:
Title
Pain scores
Description
Pain scores based on the visual analog scale and Brief Pain Inventory. Ranges from 0 to 10, with 0 being no pain and 10 being the worst imaginable pain. The intervention will be deemed effective if both outcomes are non-inferior, and at least one is superior, to the control group.
Time Frame
First postoperative 48 hours (measured at the end of the PACU stay as well as on the 1st and 2nd postoperative mornings).
Title
Total opioid consumption
Description
Total opioid consumption in oral morphine equivalents (mg) from the time of transfer to PACU through to the second postoperative morning. The intervention will be deemed effective if both outcomes are non-inferior, and at least one is superior, to the control group.
Time Frame
First postoperative 48 hours
Secondary Outcome Measure Information:
Title
Overall benefit of analgesia score (OBAS)
Description
Measures 7 different items, i.e. current pain, vomiting, itching, sweating, freezing, dizziness, and patient satisfaction related to pain management. Each item is scored from 0 to 4, with the total OBAS score ranging from 0 to 28. The lower the total OBAS score, the higher the benefit of analgesia.
Time Frame
First postoperative 48 hours (measured at the end of the PACU stay as well as on the 1st and 2nd postoperative mornings).
Title
Quality of recovery (QoR-15) score
Description
Measures 15 different items, i.e. ability to breathe easily, enjoy food, feel rested, have a good sleep, look after personal toilet and hygiene unaided, communicate with family or friends, getting support from hospital doctors and nurses, return to work or usual home activities, feel comfortable and in control, have a feeling of general well-being, as well as the presence of moderate pain, severe pain, nausea or vomiting, feeling worried or anxious, and feeling sad or depressed. Each item is scored from 0 to 10, with a total QoR-15 score ranging from 0 to 150. The higher the QoR-15 score, the better the quality of recovery in the postoperative period.
Time Frame
First postoperative 48 hours (measured at the end of the PACU stay as well as on the 1st and 2nd postoperative mornings).
Other Pre-specified Outcome Measures:
Title
Time to first opioid administration
Description
Measured in minutes
Time Frame
The amount of time from PACU admission to PACU discharge
Title
Postoperative hospital length of stay
Description
Measured in days
Time Frame
The number of days from hospital admission to hospital discharge
Title
Nausea or vomiting
Description
Measured as dichotomous outcome (yes/no)
Time Frame
First postoperative 48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults 18 to 80 years old Elective inpatient open or laparoscopic abdominal surgery General anesthesia lasting 2 hours or longer. Exclusion Criteria: 1. Planned postoperative mechanical ventilation 2. Planned regional anesthesia/analgesia 3. Perioperative gabapentin, magnesium, or nitrous oxide use 4. Pregnancy or breastfeeding 5. Morbid obesity (BMI ≥ 35 kg/m2) 6. American Society of Anesthesiologists (ASA) physical status IV-V 7. Allergy to study medications 8. Contraindication to lidocaine (severe cardiac arrhythmia) 9. Contraindication to ketamine (psychiatric disorder, substance abuse, uncontrolled hypertension, pulmonary hypertension, increased intracranial or intraocular pressure, use of monoamine oxidase inhibitors) 10. Chronic preoperative opioid use (≥ 90 morphine mg equivalents per day for > 3 months) 11. Significant preoperative hepatic dysfunction (alanine aminotransferase or aspartate aminotransferase levels > 5 times normal) or planned liver transplantation 12. Preoperative cardiac failure (left ventricular ejection fraction ≤ 40%) 13. Unable to communicate or comprehend study instructions
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Steven Minear, MD
Phone
954-290-1569
Email
minears@ccf.org
First Name & Middle Initial & Last Name or Official Title & Degree
Rebecca YS Wong, MBBS, MPH
Phone
954-789-8933
Email
wongr3@ccf.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Minear, MD
Organizational Affiliation
Cleveland Clinic Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Florida
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Minear, MD
Phone
954-290-1569
Email
minears@ccf.org
First Name & Middle Initial & Last Name & Degree
Rebecca YS Wong, MBBS, MPH
Phone
954-789-8933
Email
wongr3@ccf.org
First Name & Middle Initial & Last Name & Degree
Rebecca Y Wong, MBBS, MPH
First Name & Middle Initial & Last Name & Degree
Santiago Luis, MD
First Name & Middle Initial & Last Name & Degree
Daniel I Sessler, MD
First Name & Middle Initial & Last Name & Degree
Emanuele Lo Menzo, MD, PhD
First Name & Middle Initial & Last Name & Degree
Edward J Mascha, PhD
First Name & Middle Initial & Last Name & Degree
Chen Liang, MS
First Name & Middle Initial & Last Name & Degree
Allen Collins, AAB
First Name & Middle Initial & Last Name & Degree
Jeffrey Jacobs, MD
First Name & Middle Initial & Last Name & Degree
Tatiana Jamroz, MD
First Name & Middle Initial & Last Name & Degree
Ricardo Plata Aguilar, MD
First Name & Middle Initial & Last Name & Degree
Gerges Azer, MD
First Name & Middle Initial & Last Name & Degree
Estelle Swanson, RN
First Name & Middle Initial & Last Name & Degree
Kindlee Lindsay, ARNP
First Name & Middle Initial & Last Name & Degree
Steven Minear, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23011561
Citation
Grady MV, Mascha E, Sessler DI, Kurz A. The effect of perioperative intravenous lidocaine and ketamine on recovery after abdominal hysterectomy. Anesth Analg. 2012 Nov;115(5):1078-84. doi: 10.1213/ANE.0b013e3182662e01. Epub 2012 Sep 25.
Results Reference
background
PubMed Identifier
29864216
Citation
Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, Hollmann MW, Poepping DM, Schnabel A, Kranke P. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev. 2018 Jun 4;6(6):CD009642. doi: 10.1002/14651858.CD009642.pub3.
Results Reference
background
PubMed Identifier
15621365
Citation
Elia N, Tramer MR. Ketamine and postoperative pain--a quantitative systematic review of randomised trials. Pain. 2005 Jan;113(1-2):61-70. doi: 10.1016/j.pain.2004.09.036.
Results Reference
background
PubMed Identifier
29390443
Citation
Ye F, Wu Y, Zhou C. Effect of intravenous ketamine for postoperative analgesia in patients undergoing laparoscopic cholecystectomy: A meta-analysis. Medicine (Baltimore). 2017 Dec;96(51):e9147. doi: 10.1097/MD.0000000000009147.
Results Reference
background
PubMed Identifier
29384867
Citation
Zhao JB, Li YL, Wang YM, Teng JL, Xia DY, Zhao JS, Li FL. Intravenous lidocaine infusion for pain control after laparoscopic cholecystectomy: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Feb;97(5):e9771. doi: 10.1097/MD.0000000000009771.
Results Reference
background
PubMed Identifier
23044681
Citation
Sun Y, Li T, Wang N, Yun Y, Gan TJ. Perioperative systemic lidocaine for postoperative analgesia and recovery after abdominal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum. 2012 Nov;55(11):1183-94. doi: 10.1097/DCR.0b013e318259bcd8. Erratum In: Dis Colon Rectum. 2013 Feb;52(2):271.
Results Reference
background

Learn more about this trial

Perioperative Lidocaine and Ketamine in Abdominal Surgery

We'll reach out to this number within 24 hrs